| Demographics and other baseline characteristics | |||
|---|---|---|---|
| EU | Japan |
4 Countries (KR/TW/HK/TH) |
|
|
Total [N = 13,133] |
Total [N = 11,330] |
Total [N = 3359] |
|
| Weight [kg], mean (SD) | 81.0 ± 17.3 | 60.0 ± 12.8 | 65.9 ± 12.4 |
| Age [years], mean (SD) | 73.6 ± 9.5 | 74.2 ± 10.1 | 71.7 ± 9.6 |
| Age [years], n (%) | |||
| < 65 | 1995 (15.2) | 1666 (14.7) | 678 (20.2) |
| [65, 74] | 4449 (33.9) | 3710 (32.7) | 1296 (38.6) |
| [75, 84] | 5313 (40.5) | 4354 (38.4) | 1122 (33.4) |
| ≥ 85 | 1375 (10.5) | 1600 (14.1) | 263 (7.8) |
| Calc. eGFR (CG formula) [ml/min/1.73m2], n (%) | |||
| ≥ 80 | 4127 (36.1) | 2417 (21.9) | 621 (20.7) |
| (50; 79) | 4914 (43.0) | 5072 (46.0) | 1435 (47.8) |
| [30; 49] | 2107 (18.4) | 2990 (27.1) | 755 (25.1) |
| [15; 29] | 289 (2.5) | 542 (4.9) | 190 (6.3) |
| < 15 | 3 (0.0) | 6 (0.1) | 2 (0.1) |
| Edoxaban dose at baseline, n (%) | |||
| 60 mg | 10,036 (76.4) | 3123 (27.6) | 1670 (49.7) |
| Recommended | 8916 (67.9) | 2866 (25.3) | 1293 (38.5) |
| Non‐Recommended | 1120 (8.5) | 257 (2.3) | 377 (11.2) |
| 30 mg | 3097 (23.6) | 8207 (72.4) | 1689 (50.3) |
| Recommended | 1992 (15.2) | 6777 (59.8) | 1088 (32.4) |
| Non‐recommended | 1105 (8.4) | 1430 (12.6) | 601 (17.9) |
Calc, calculated; CG, Cockcroft Gault; eGFR, estimated glomerular filtration rate; EU, Europe; HK, Hong Kong; n, number; TH, Thailand; TW, Taiwan; SD, standard deviation.